Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy

Immunotherapy has fundamentally changed the landscape of cancer treatment. However, only a subset of patients respond to immunotherapy, and a significant portion experience immune-related adverse events (irAEs). In addition, the predictive ability of current biomarkers such as programmed death-ligan...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yeonggyeong, Kim, Min Jeong, Choi, Yoonhee, Kim, Na Hyun, Kim, Leeseul, Hong, Seung Pyo Daniel, Cho, Hyung-Gyo, Yu, Emma, Chae, Young Kwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961104/
https://www.ncbi.nlm.nih.gov/pubmed/35347071
http://dx.doi.org/10.1136/jitc-2021-003566